RMC-6236 with Pembrolizumab: RMC-LUNG-101B is an arm of the Phase 1b study of RMC-6236 in combination with pembrolizumab, with or without chemotherapy, in patients with RAS mutant NSCLC. A total of 20 ...

DELHI, DELHI, INDIA, November 28, 2024 /EINPresswire / -- The Growth of the KRAS Inhibitors Market is expected to be mainly driven by increasing incidence, a rise in awareness and access to treatment, ...

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma, continuing a move into ...

Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute ...

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...

SOS1 is a guanine nucleotide exchange factor (GEF) that activates KRAS, and recent preclinical studies have demonstrated that combining KRAS and EGFR inhibitors with SOS1 inhibitors can overcome ...

"KRAS inhibitors are the new frontier in pancreatic cancer. They may have a big impact, but we also know that resistance will ...

In a paper titled, “A KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities”, researchers from D3 ...

an oral KRAS G12D (ON/OFF) inhibitor." Avutometinib and Defactinib Combination in Low-Grade Serous Ovarian Cancer (LGSOC) Completed the rolling New Drug Application (NDA) submission for the ...

Detailed price information for Cogent Biosciences Inc (COGT-Q) from The Globe and Mail including charting and trades.

Third Quarter 2024 and Recent Updates Avutometinib and Defactinib Combination in Low-Grade Serous Ovarian Cancer (LGSOC) Avutometinib in Combination with KRAS G12C Inhibitors in Non-Small Cell ...